We are unifying our identity under a single name – GI Cancer Trials – to better reflect our purpose and make it easier for people to understand who we are and what we do.
For over three decades, our clinical trials have been conducted as the Australasian Gastro-Intestinal Trials Group (AGITG). To support this work, we later established the GI Cancer Institute as the public and fundraising arm in the mid-2000s.
This dual branding has caused confusion, duplicated effort, and made it harder for people to clearly understand who they are supporting.
By adopting a single, consistent name, we can reduce this confusion, strengthen trust, and present a clearer identity to the public, partners, and researchers alike.
While our name is changing, what will not change is what matters most – building a better future for people with GI cancer through clinical trials.
Below are answers to some common questions that you may have.
A. We are unifying our identity under a single name to better reflect who we are and what we do, and to build stronger trust with our stakeholders.
For over three decades, our clinical trials have been conducted as the Australasian Gastro-Intestinal Trials Group (AGITG). To support this work, we later established the GI Cancer Institute as the public and fundraising arm in the mid-2000s.
This dual branding has caused confusion, duplicated effort, and made it harder for donors to clearly understand who they are supporting.
By adopting a single, consistent name, we can reduce this confusion, strengthen trust, and present a clearer identity to the public, partners, and researchers alike.
The change is part of our 2025–2030 Strategy, which sets a bold vision for growth and impact. A simpler, more recognisable name – GI Cancer Trials – will help us connect more effectively and amplify our work in GI cancer research.
A. GI Cancer Trials is a name that speaks directly to our core purpose. It’s clear, memorable, and easy to pronounce.
Clinical trials are the only way to discover new and better treatments for people with GI cancer. GI Cancer Trials puts this at the forefront, raising awareness of our unique role in cancer research and strengthening the case for greater participation and support.
A. Nothing. Our commitment to improving outcomes for people with GI cancer remains unchanged. Our research, staff, contact details and website address are not changing.
A. Our new name launches publicly on 3 February 2026. From then, you will start to see communications appear from GI Cancer Trials and with our refreshed logo.
We will utilise GI Cancer Trials (formerly AGITG & GI Cancer Institute) for up to 12 months while the community becomes familiar with our new name.
A. The new name helps us more clearly communicate our mission and build stronger connections with supporters, researchers, and the community so we can ultimately do more for people with cancer.
A. No – your donation still supports life-saving GI cancer research, in the same way it always has. Our new name simply helps us tell that story more effectively.
A. Thank you for your ongoing support of our research, we couldn’t conduct our trials without the dedication of our generous GI cancer community.
Please be rest assured that our commitment to undertaking vital GI cancer research is unchanged. Our leadership, staff and researchers remain the same, as does our research program that brings new GI cancer trials to patients who need them most.
The new name is about clearer communication – the rest of us remains the same. We look forward to your continued support.
A. No – our previous trading names, GI Cancer Institute and Australasian Gastro-Intestinal Trials Group will continue to be business names, and our legal company name, Australasian Gastro-Intestinal Trials Group, is not changing. The ABN (34 093 854 267) remains the same.
A: Yes – you’ll continue to receive newsletters, updates, and invitations as always, now under the GI Cancer Trials name.
A. Please contact us at info@gicancer.org.au and we can direct your question to the relevant team.